Newsletter · · Ashutosh Agarwal

Humana Sheds 600,000 Members as Centene Swings to a Billion Dollar Profit - Managed Care Under Pressure - Week of August 1, 2026

A synthesis of what healthcare podcasts said about the second-quarter managed-care prints for the week of July 25 to August 1, 2026, including Humana's 600,000 member Medicare Advantage exit, Centene's swing from loss to profit, HCA's larger ACA hit, and PBM reform clearing a House committee.

Managed Care Under Pressure

Week of July 25 to August 1, 2026: Q2 Prints Land, Payers Shed Members and Rebuild Margins

For seven weeks this newsletter has been waiting for one thing: the moment podcasts stopped talking about managed care in the abstract and started reacting to the actual second-quarter (Q2'26) numbers. This week that finally happened. The picture that emerged is consistent and, for the insurers, encouraging in a narrow way: the big health plans are getting healthier by getting smaller. They are deliberately walking away from members and markets that cost too much, and their margins are recovering because of it. The people losing coverage are the ones absorbing the pain.

TL;DR

  • The Q2'26 earnings recap finally hit the podcasts, and the theme is "shrink to fix." Humana (HUM) said its individual Medicare Advantage pre-tax margin should roughly double this year (excluding a Star-ratings wildcard) and is dropping about 600,000 MA members; Centene (CNC) swung from a loss of more than $250 million in Q2'25 to over $1 billion in profit in Q2'26 by pricing up and shedding roughly 2 million exchange members. CVS is the last big payer left to report.
  • The ACA subsidy cliff is now clearly helping insurers and hurting hospitals. Insurers pre-filed higher rates and let healthier customers walk; hospitals are eating the newly uninsured. HCA now sees a $1.0 to $1.2 billion full-year hit to its payer mix.
  • Two policy machines are grinding on the cost side: a federal PBM-reform bill cleared a House committee 40-2 (with the per-violation fine jacked from $10,000 to $1 million), and Medicaid work requirements went live, with the first people in the country losing coverage as of today.

What's new

1) Humana is dropping ~600,000 Medicare Advantage members and telling investors margins should roughly double. On the Becker's Healthcare Podcast (July 29), Becker's payer journalist Jacob Emerson (trade press) recapped the just-reported Q2'26 payer and hospital calls. On Humana (HUM): "their individual Medicare Advantage pre-tax margin should double this year, excluding STARS headwinds," and the company "just announced today they're going to drop 600,000 members through targeted exits," either leaving markets outright or dropping PPO plans and trying to shuffle members into cheaper HMO or narrow-network products. The same 600,000 figure was flagged independently on The Seven Figures Or Bust Podcast (July 31), a Medicare insurance-agent show, which said a carrier's chief financial officer "publicly came out and said they were gonna be expecting to terminate 600,000 members this AEP on Medicare Advantage plans." Why it matters: this is the clearest sign yet that MA margin recovery is real but bought with membership. The "STARS headwinds" caveat is the catch, Star ratings (the CMS quality scores that drive bonus payments) remain, in Emerson's words, "a bit of a wild card right now across the entire industry, given the mess that that is between the insurers and the government."

2) Centene turned a $250 million loss into a $1 billion-plus profit by pricing up and letting exchange members leave. Also via Emerson on Becker's (July 29): Centene (CNC) "had over a $250 million loss in the same quarter last year, and then they recorded over a billion dollars in profit this year." The mechanism: Centene's actuaries saw the ACA enhanced-subsidy expiration coming, pre-filed a second set of higher rates with states, and let the healthy customers who balked at higher premiums walk, roughly 2 million marketplace members lost, but the 2026 marketplace margin went up. Emerson's summary: "It's a loss to the consumer, but the insurers seem to do OK." Why it matters: CNC was the name most exposed to the subsidy cliff, and the read is that management got ahead of it. The trade-off is a smaller, sicker-on-paper book carried at a better price.

3) The ACA subsidy cliff is a payer tailwind and a hospital headwind, and hospitals are quantifying the damage. On the same Becker's episode, Emerson walked through the hospital Q2'26 calls (HCA, Tenet, Community Health, Universal Health). Hospitals had assumed 80-85% of people who lost subsidies would become uninsured and 15% would find other coverage; instead "almost 100% of those people ended up not getting coverage elsewhere." HCA now pegs the full-year hit to its payer mix at "somewhere between a billion and 1.2 billion," up from an earlier $600 to $900 million, roughly a $400 million swing, against a full-year adjusted EBITDA outlook of about $15.4 to $16.1 billion. Tenet, by contrast, had a strong quarter (exchange patients are only about 5.5% of its revenue) and leaned on its ambulatory-surgery mix. Why it matters: the same policy change that fattens insurer margins thins hospital margins. Emerson's blunt take on the hospital complaints: it's "a mixture" of real pain and political positioning, because these companies are "still so incredibly profitable."

4) A federal PBM-reform bill cleared a House committee, with a 100x bigger fine. On the Pharmacy Podcast Network (July 31), pharmacy advocates described HR 6610, the "Pharmacists Fight Back Act," being marked up and voted out of the House Oversight Committee 40-2, described as "the most comprehensive" PBM bill yet to clear committee. It targets reimbursement, patient "steering," and "the ability for PBMs to massively mark up medications at pharmacies that they own," and bans retroactive fees. The per-violation fine was raised during markup from $10,000 to $1 million; the concession was a two-year (rather than one-year) runway to take effect. The advocates also noted Senator Elizabeth Warren used an Armed Services subcommittee hearing to target Express Scripts' practices in the TRICARE military pharmacy program. Why it matters: pointed directly at the vertically integrated pharmacy-benefit arms, CVS's Caremark, UnitedHealth's Optum Rx, and Cigna's Express Scripts. Clearing committee is a real (if early) step, and the "pharmacies that they own" language is aimed squarely at the own-the-whole-stack model.

5) Medicaid work requirements are live, the first coverage losses in the country happen today. On Tradeoffs (July 30), Nebraska Medicaid Director Drew Goncharowski (state official) explained his state started work requirements roughly eight months ahead of the January 1, 2027 federal deadline, with the first terminations landing "a few days away from August 1st." Nebraska expects a small first batch (under ~250 people), but consultancy Manatt Health estimates up to 30,000 Nebraskans could lose Medicaid by 2028. Nationally, host Dan Gorenstein noted, "20 million people across 44 states will be subject to some version of these rules." A recent survey found 55% of Medicaid recipients were completely unaware of the new requirements. The same policy thread ran through The Rural Impact (July 30) and CareTalk (July 31). Why it matters: this is the front edge of Medicaid enrollment shrinking, and the members most likely to churn off are often the cheapest, which can worsen the acuity (average sickness) of the members who remain. That is a direct read into Centene (CNC) and Molina (MOH).

The debate

Bull: the worst is behind them, and 2027 is a repricing year. The Q2'26 prints back this up. Insurers are deliberately exiting money-losing membership, raising prices ahead of policy changes, and rebuilding margins that had been crushed for 18 to 24 months. Humana guiding individual MA margins to roughly double and Centene swinging to a billion-dollar profit are exactly what a bottoming-and-recovering cycle looks like. The ACA subsidy cliff, feared as a disaster, is so far a net positive for the plans because they let the price-sensitive customers leave.

Bear: the recovery is being manufactured by shrinking, and the cost curve underneath is still rising. Two hard numbers cut against the bull. First, medical costs are not calming down: on PwC's Next in Health (July 30), PwC's actuaries put the 2027 medical cost trend near "eight and a half, 9%," still running about twice wage and economic growth. On Medicine: The Truth (July 29), former Permanente Group CEO Dr. Robert Pearl noted drug spending rose 11% last year, the fastest of any category, driven by GLP-1 weight-loss drugs. Second, the margin gains lean on membership cuts, which is not a repeatable growth engine, you can only shrink so far. And the "STARS headwinds" wildcard Emerson flagged means the bonus-payment fight between insurers and CMS is unresolved. A plan that improves margin by dropping 600,000 members and dropping Star ratings has not actually fixed anything durable.

The swing factor: whether 2027 bids and benefit designs let the plans hold these margins without continuing to shed members. Growth-plus-margin is the bull case; margin-only-by-shrinking is the bear case. This week's tape supports the second.

Stocks in play

  • UNH (UnitedHealth). Bull: squarely in the multi-year MA margin rebuild, "dropping millions of members this year" (Emerson) to protect profitability. Bear: owns Optum Rx, the PBM most exposed to HR 6610's "pharmacies that they own" language; Star ratings dispute unresolved. Next catalyst / number to watch: does the margin-recovery narrative hold as it laps its own membership cuts.
  • CVS (CVS Health / Aetna). Bull: the last big payer left to report, so the setup others just delivered (subsidy cliff helping, MA margins recovering) is the template. Bear: Caremark is the single largest target of the PBM bill; Aetna carries MA cost and Star exposure. Next catalyst: the Q2'26 print itself, Aetna's medical benefit ratio (MBR) and any 2027 benefit-design color. (Per Emerson, CVS had not reported yet as of this week's tape.)
  • HUM (Humana). Bull: most MA-levered name and guiding individual MA pre-tax margin to roughly double this year (ex-Star); cutting ~600,000 members to get there. Bear: that recovery is bought with membership, and Star ratings are the explicit wildcard on the guide. Next catalyst: whether 2027 bids let it stop shrinking; resolution of the Star-ratings dispute.
  • ELV (Elevance). Bull: did its market-exit and PPO-pruning "last year" (Emerson), so it is arguably further into the rebuild than peers. Bear: ACA and Medicaid exposure as the subsidy cliff and work requirements bite. Next catalyst: Medicaid acuity and MA cost trends in the numbers. (Read-through this week.)
  • CNC (Centene). Bull: the standout turnaround this week, over $1 billion Q2'26 profit versus a $250 million-plus loss a year ago, with a higher 2026 marketplace margin despite losing ~2 million exchange members. Bear: it is the most exposed name to both the ACA subsidy cliff and Medicaid work requirements; the book is smaller and the political backdrop is hostile. Next catalyst: 2027 exchange enrollment and whether Medicaid acuity climbs as healthier members churn off.
  • MOH (Molina). Bull: disciplined Medicaid underwriter. Bear: the most Medicaid-levered name into work-requirement coverage losses now going live (20 million people across 44 states in scope). Next catalyst: Q2'26 medical cost ratio and any read on Medicaid rate adequacy versus rising acuity. (Read-through only.)
  • CI (Cigna). Bull: out of Medicare Advantage, so it sidesteps the MA cost and Star-ratings fights; Evernorth/Express Scripts is the growth engine. Bear: Express Scripts is directly in the PBM-reform crosshairs, including Senator Warren's TRICARE hearing. Next catalyst: Evernorth growth and the trajectory of the PBM bill. (Read-through only this week.)

Read-throughs

  • Medicaid and exchange insurers (CNC, MOH, ELV): two forces at once. The ACA subsidy cliff is, counterintuitively, helping margins because plans pre-priced for it and let the healthy leave (Centene is the proof). But Medicaid work requirements, live as of today, 20 million people in scope across 44 states (Tradeoffs), will shrink Medicaid rolls and can leave a sicker remaining pool. Watch acuity versus rate adequacy.
  • PBMs and Optum-style arms (Caremark/CVS, Optum Rx/UNH, Express Scripts/CI): the regulatory temperature keeps rising. HR 6610 cleared committee 40-2 with a $1 million-per-violation fine and language aimed at PBM-owned pharmacies (Pharmacy Podcast Network). Two-year phase-in softens the near-term hit, but the direction of travel is one-way.
  • Hospitals and providers (the other side of utilization): the mirror image of insurer strength. HCA's $1.0 to $1.2 billion payer-mix hit and the "almost 100%" of dropped-subsidy patients becoming uninsured (Becker's) show hospitals absorbing the cost the insurers shed. Emerson also flagged rising insurer-provider tension: tougher prior authorization, clawbacks, audits, and "a lot of big lawsuits filed recently by big health systems over MA reimbursement."
  • GLP-1 cost exposure: the near-term math is still negative for payers. On PwC's Next in Health, Phil Sclafati said GLP-1 prices have fallen "60, 70 percent," but "volume has skyrocketed and could further 2x, 3x and 4x from there. There simply isn't enough price left to offset," pegging GLP-1 coverage at "30, 40, 50 dollars per member per month" alone, and predicting "a pretty good amount" of employers will drop or restrict weight-loss coverage while keeping it for diabetes. Dr. Pearl on Medicine: The Truth put the cost-effectiveness threshold at roughly $200/month versus brand retail prices "double that." He also flagged Medicare's new BRIDGE pilot covering GLP-1s for weight loss at a $50/month copay, but it is an 18-month pilot, not guaranteed to continue.

What changed vs last week

Last week the story was a genuinely quiet earnings tape, with the action in Washington (the No Surprises Act arbitration reversal and claims-data transparency bills). This week the earnings tape re-engaged, exactly as flagged. For the first time this cycle, podcasts recapped the actual Q2'26 payer and hospital numbers: Humana's 600,000-member cut and doubling MA margin guide, Centene's swing to a billion-dollar profit, and HCA's larger ACA hit.

The one net-new policy thread that hardened: the Part D premium-stabilization subsidy is being sunset a year early for 2027 (Seven Figures Or Bust), but that is a standalone drug-plan (PDP) issue, not a Medicare Advantage one.